Claims
- 1. A method of screening for a compound that is an antagonist of calcitonin gene related peptide (αCGRP), said method comprising:
(A) exposing to said compound a mutant mouse, whose genome comprises a homozygous disruption of the αCGRP gene, wherein said disruption results in said mutant mouse lacking detectable levels of endogenous αCGRP as compared to a wild type mouse; and (B) determining the response of said mutant mouse to a nociceptive-inducing stimulus, wherein a difference in response compared to a wild type mouse is indicative of the compound functioning to alter αCGRP activity.
- 2. The method of claim 1, wherein the disruption of (A) comprises the insertion of a transgene.
- 3. The method as claimed in claim 1, wherein said method comprises determining said response by the tail-flick method and said compound inhibits αCGRP activity in the mutant mouse.
- 4. The method as claimed in claim 1, wherein said method comprises determining said response by the hot plate method and said compound inhibits αCGRP activity in the mutant mouse.
- 5. The method of claim 1, wherein said method comprises determining said response by carragenan rat paw edema assay and said compound inhibits αCGRP activity in the mutant mouse.
- 6. A compound, which is an antagonist of αCGRP, identified by the method of any one of claims 1 to 5.
- 7. The compound of claim 6, which is a peptide, small organic molecule, antisense molecule, or a triple helix molecule.
- 8. The compound of claim 6, which is a monoclonal antibody.
- 9. A method for ameliorating neurogenic inflammatory pain comprising:
administering a compound capable of specifically inhibiting αCGRP activity to an animal having neurogenic inflammatory pain symptoms in an amount sufficient to inhibit the αCGRP activity in the animal so that symptoms of neurogenic inflammatory pain are ameliorated.
- 10. A method for ameliorating physical opiate withdrawal comprising:
administering a compound capable of specifically inhibiting αCGRP activity to an animal having physical opiate withdrawal symptoms in an amount and for a time sufficient to inhibit the αCGRP activity in the animal so that symptoms of physical opiate withdrawal are ameliorated.
- 11. A method for ameliorating neurogenic inflammatory pain comprising:
administering a compound capable of specifically inhibiting expression of αCGRP to an animal having neurogenic inflammatory pain symptoms in an amount and for a time sufficient to inhibit the expression of αCGRP in the animal so that symptoms of neurogenic inflammatory pain are ameliorated.
- 12. A method for ameliorating physical opiate withdrawal comprising:
administering a compound capable of specifically inhibiting expression of αCGRP to an animal having physical opiate withdrawal symptoms in an amount and for a time sufficient to inhibit the expression of αCGRP in the animal so that symptoms of physical opiate withdrawal are ameliorated.
- 13. The compound of claim 6, wherein said compound specifically inhibits the αCGRP activity.
- 14. The compound of claim 6, wherein said compound specifically inhibits the αCGRP expression.
- 15. A pharmaceutical composition comprising the compound of claim 6 along with at least one physiologically acceptable carrier or excipient.
- 16. A compound for ameliorating neurogenic inflammatory pain an/or physical opiate withdrawal, wherein said compound is an antagonist of calcitonin gene related peptide αCGRP.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is based on and claims the benefit of U.S. Provisional Application No. 60/273,349, filed Mar. 6, 2001 (attorney docket no. 03495.6062) The entire disclosure of this application is relied upon and incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60273349 |
Mar 2001 |
US |